Developing a standard phantom of the human eye for internal dose assessment
This work is a continuation of the development of Astatine-211, a new α-emitter radiopharmaceutical for treating cancer of the thyroid gland. The internal doses in a patient’s organs, e.g., the eye and the lens of the eye, are estimated using the GEANT-4 software for calculating absorbed doses in different organs with allowance for the complex anatomy of the human body. The results of calculations show that with the same therapeutic dose in an irradiated organ (the thyroid gland), the use of Astatine-211 radiopharmaceutical reduces the radiation dose of the eye by several orders of magnitude, compared to the use of pharmaceuticals containing 131I.